OMB control number 0910–0338; the collections of information in §§ 201.56 and 201.57 for the content and format requirements for labeling of human prescription drug and biological products have been approved under OMB control number 0910–0572.

In addition, the following collections of information in FDA's guidances have been approved by OMB (*https://www.fda.gov/regulatory-information/search-fda-guidance-documents*):

- Collections in FDA's draft guidance for industry entitled ''Formal Meetings Between the FDA and Sponsors and Applicants for PDUFA Products'' have been approved under OMB control number 0910–0429.
- Collections in FDA's guidance for industry entitled ''Special Protocol Assessment'' have been approved under OMB control number 0910–0470.
- Collections in FDA's guidance for industry entitled ''Establishment and Operation of Clinical Trial Data Monitoring Committees'' have been approved under OMB control number 0910–0581.
- Collections in FDA's guidance for industry entitled ''Oversight of Clinical Investigations—A Risk-Based Approach to Monitoring'' have been approved under OMB control number 0910–0733.
- Collections in FDA's guidance for industry entitled ''Expedited Programs for Serious Conditions—Drugs and Biologics'' have been approved under OMB control number 0910–0765.
- Collections in FDA's guidance for industry entitled ''E6(R2) Good Clinical Practice: Integrated Addendum to ICH E6(R1)'' have been approved under OMB control number 0910–0843.

III. Electronic Access

Persons with access to the internet may obtain the guidance at *https://www.fda.gov/drugs/guidance-compliance-regulatory-information/guidances-drugs, https://www.fda.gov/vaccines-blood-biologics/guidance-compliance-regulatory-information-biologics, https://www.fda.gov/regulatory-information/search-fda-guidance-documents,* or *https://www.regulations.gov.*

Dated: February 24, 2022.

Lauren K. Roth,

Associate Commissioner for Policy.

[FR Doc. 2022–04398 Filed 3–1–22; 8:45 am]

BILLING CODE 4164–01–P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Meeting of the Vaccines Federal Implementation Plan

AGENCY: Department of Health and Human Services, Office of the Secretary, Office of the Assistant Secretary for Health, Office of Infectious Disease and HIV/AIDS Policy.

ACTION: Notice.

SUMMARY: The Department of Health and Human Services' Office of Infectious Disease and HIV/AIDS Policy in the Office of the Assistant Secretary for Health announces that the draft *Vaccines Federal Implementation Plan 2021–2025* is available for public comment. The *Vaccines Federal Implementation Plan* is a companion document to the *Vaccines National Strategic Plan 2021–2025* (VNSP), which was published in January 2021. The *Vaccines Federal Implementation Plan* is a compilation of federal agency immunization activities that collectively advance the goals of the VNSP. Its target audience is other federal agencies and external partners who work in the area of vaccination. The public will be interested in how the implementation plan documents federal agency efforts. It does not outline mandates or other COVID–19 response measures.

DATES: The public comment period for the Vaccines Federal Implementation Plan starts on February 28, 2022 at 9 a.m. ET and ends on March 29, 2022 at 5 p.m. ET. All comments must be received by 5 p.m. ET on March 29, 2022 to be considered.

ADDRESSES: All comments must be submitted electronically to *nvp.rfi@hhs.gov.*

FOR FURTHER INFORMATION CONTACT: David Kim, MD, MA, Director, Division of Vaccines, Office of Infectious Disease and HIV/AIDS Policy, Office of the Assistant Secretary for Health, U.S. Department of Health and Human Services, Room L616, Switzer Building, 330 C St. SW, Washington, DC 20024. Phone: 202–795–7697; Email: *nvp.rfi@hhs.gov.*

Dated: February 17, 2022.

David Kim,

Designated Federal Officer, Vaccines Federal Implementation Plan, Office of the Assistant Secretary for Health.

[FR Doc. 2022–04327 Filed 3–1–22; 8:45 am]

BILLING CODE 4150–44–P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health

National Toxicology Program Board of Scientific Counselors; Announcement of Meeting; Request for Comments

AGENCY: National Institutes of Health, HHS.

ACTION: Notice.

SUMMARY: This notice announces the next meeting of the National Toxicology Program (NTP) Board of Scientific Counselors (BSC). The BSC, a federally chartered, external advisory group composed of scientists from the public and private sectors, will review and provide advice on programmatic activities. This meeting is a virtual meeting and is open to the public. Written comments will be accepted and registration is required to present oral comments.

DATES:

Meeting: Scheduled for April 19, 2022, 12:30 p.m.–2:00 p.m. Eastern Standard Time (EST). Ending times are approximate; meeting may end earlier or run later.

Written Public Comment Submissions: Deadline is April 12, 2022.

Registration for Oral Comments: Deadline is April 12, 2022.

ADDRESSES:

Meeting Web Page: The preliminary agenda, registration, and other meeting materials will be available at *https://ntp.niehs.nih.gov/go/165* by March 14, 2022.

Virtual Meeting: The URL for viewing the virtual meeting will be provided on the meeting web page the day before the meeting.

FOR FURTHER INFORMATION CONTACT: Dr. Mary Wolfe, Designated Federal Official for the BSC, Office of Policy, Review, and Outreach, Division of NTP, NIEHS, P.O. Box 12233, K2–03, Research Triangle Park, NC 27709. Phone: 984–287–3209, Fax: 301–451–5759, Email: *wolfe@niehs.nih.gov.* Hand Deliver/Courier address: 530 Davis Drive, Room K2130, Morrisville, NC 27560.

SUPPLEMENTARY INFORMATION: The BSC will provide input to the NTP on programmatic activities and issues. The preliminary agenda topics include presentations on a contract concept: Bioinformatics Support for the NIEHS. The preliminary agenda, roster of BSC members, background materials, public comments, and any additional information, when available, will be posted on the BSC meeting web page (*https://ntp.niehs.nih.gov/go/165*) or